Stay updated on Pembrolizumab Plus Paclitaxel in HER2- Breast Cancer Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab Plus Paclitaxel in HER2- Breast Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab Plus Paclitaxel in HER2- Breast Cancer Clinical Trial page

  1. Check
    2 days ago
    Change Detected
    Summary
    The page's revision label was updated from v3.6.3 to v3.6.4, indicating a minor update to the page metadata. No substantive study details or user-facing content were changed.
    Difference
    0.1%
    Check dated 2026-07-25T12:47:26.000Z thumbnail image
  2. Check
    9 days ago
    No Change Detected
  3. Check
    16 days ago
    No Change Detected
  4. Check
    24 days ago
    Change Detected
    Summary
    The page now displays a new revision label v3.6.3, replacing the previous v3.6.2.
    Difference
    0.1%
    Check dated 2026-07-04T04:12:13.000Z thumbnail image
  5. Check
    31 days ago
    Change Detected
    Summary
    The revision tag on the page was updated to v3.6.2, indicating a newer version of the page/document.
    Difference
    0.1%
    Check dated 2026-06-27T01:52:15.000Z thumbnail image
  6. Check
    38 days ago
    Change Detected
    Summary
    Removed multiple study documents (Informed Consent Form and Study Protocol and Statistical Analysis Plan) and several site-wide footer/navigation items from the study record page. This change reduces direct access to core documents and information resources for users reviewing this trial.
    Difference
    21%
    Check dated 2026-06-19T22:50:48.000Z thumbnail image
  7. Check
    45 days ago
    Change Detected
    Summary
    The page now includes new sections to guide users ('How to Read a Study Record', 'Common Questions', 'How to Join a Study') and notes that recruitment is closed ('No longer looking for participants'). In addition, the 'Intervention/Treatment' heading has been standardized and the revision tag updated to 'Revision: v3.6.0' (replacing 'Revision: v3.5.5').
    Difference
    0.4%
    Check dated 2026-06-12T16:54:29.000Z thumbnail image
  8. Check
    52 days ago
    Change Detected
    Summary
    The page now displays Revision: v3.5.5 in the footer, replacing the previous version and indicating a minor page update.
    Difference
    0.1%
    Check dated 2026-06-05T13:41:47.000Z thumbnail image

Stay in the know with updates to Pembrolizumab Plus Paclitaxel in HER2- Breast Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Plus Paclitaxel in HER2- Breast Cancer Clinical Trial page.